FSD Pharma Inc. (NASDAQ: HUGE) shares are -43.82% down in the year-to-date (YTD) period and have moved 7.39% or $0.21 higher in the latest trading session. However, stock’s trailing 12-month performance remains nearly +27.61% lower. Comparatively, the stock is -78.21% down YTD and 2.69% over the trailing 3-month period. If we look at the shorter duration, its week performance is 0.00% and -18.45% over the month.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
0 of the 1 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 1 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $3.05. The forecasts give the FSD Pharma Inc. stock a price target range of $8.36 on the higher side while at least one analyst think the stock could plunge to a low of $8.36. The two limits represent an upside potential of 63.52% or 63.52%.
Advaxis Inc. (NASDAQ:ADXS), on the other hand, is trading around $0.48 with a market cap of $30.53M and analyst research firms have a positive stance on its shares. Some analysts are even forecasting $0 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Advaxis Inc. (ADXS) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
ADXS’s operating expenses over the recent quarter were at -$6.32 million. This represented a 2628.4% of the company’s total revenues which amounted $0.25 million. With this in place, we can see that the company’s diluted EPS declined -$0.10 on the year-over-year period, shrinking to -$1.59 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Jul 2020), the total assets figure advanced to $45.21 million from $51.35 million over the previous quarter. The cash flow from operating activities totaled -$13.42 million, significantly higher than the -$19.77 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$13.42 million.
Insiders have transacted a total of 3 times at Advaxis Inc. over the last 6 months, with insider purchases undertaken 0 times and accounting for 0 shares. Insider sales totaled 3,000 shares over the same period, with these deals completed in 3 transactions. Looking at these numbers, we realize that net purchases over that period are -3.0 shares. Insiders now hold a total of 289.56k shares after the latest sales, with -1.00% net shares purchased.
Insiders own 0.47% of the company shares, while shares held by institutions stand at 19.70% with a share float percentage of 48.23M. Investors are also buoyed by the number of investors in a company, with Advaxis Inc. having a total of 39 institutions that hold shares in the company.